News tagged ‘OvarianCancer’ clear
Dana-Farber researchers have demonstrated a molecular strategy that they say could make a much larger variety of tumors treatable with PARP inhibitors, a promising new class of cancer drugs.
Tags: BreastCancer, OvarianCancer, GynecologicCancers
- Dana-Farber/Brigham and Women's Cancer Center has joined forces with the
Massachusetts Chapter of the National Ovarian Cancer Coalition and The
M. Patricia Cronin Foundation to launch a month-long campaign to promote
ovarian cancer awareness.
Tags: OvarianCancer
- A widely used diabetes drug dramatically boosted the potency of
platinum-based cancer drugs when administered together to a variety of
cancer cell lines and to mice with tumors, scientists from Dana-Farber
report.
Tags: LungCancer, OvarianCancer
Scientists from Brigham and Women's Hospital and Dana-Farber Cancer Institute and their colleagues have found a genetic marker that predicts which aggressive "triple negative" breast cancers and certain ovarian cancers will likely respond to platinum-based chemotherapies.
Tags: BasicResearch, BreastCancer, Genomics, OvarianCancer, GynecologicCancers
A new Dana-Farber Cancer Institute study suggests there is a direct connection between high-grade serous ovarian cancer (HGSOC) and fallopian tubes. The finding could aid in the development of better treatments for the cancer.
Tags: OvarianCancer, GynecologicCancers
- On Sept. 6 at Boston City Hall Plaza, Dana-Farber/Brigham and Women's Cancer Center, along with a coalition of six organizations, launched a month-long campaign to promote ovarian cancer awareness. The group, known as OvarianCancerAwareness.org, is dedicated to educating the public about the subtle symptoms of ovarian cancer to promote early detection.
Tags: OvarianCancer
As part of Project Achilles, aimed at finding the "Achilles heel" of cancer, researchers from Dana-Farber Cancer Institute, Harvard and the Broad Institute of MIT examined cells from over 100 tumors, including 25 ovarian cancer tumors, finding promising new targets for genetic research.
Tags: BasicResearch, OvarianCancer, GynecologicCancers
The discovery of a subtype of ovarian cancer that could account for up to one-third of all serous ovarian cancers may lead to clinical trials using anti-angiogenic drugs that are already being tested in other cancers.
Tags: OvarianCancer, GynecologicCancers
Research led by Dana-Farber Cancer Institute scientists may soon enable doctors to determine which patients with the most common form of ovarian cancer – high-grade serous ovarian cancer (HGSOC) – are most likely to benefit from a certain class of drugs.
Tags: OvarianCancer, GynecologicCancers